Industry Revenues:

• Biotechnology: 45%
• Pharmaceutical Industry: 35%
• Academic Research: 20%

TOP 3 Markets:

• USA: 40%
• Europe: 35%
• Asia-Pacific: 15%

ChemoMetec A/S generates the majority of its revenues from the biotechnology industry, followed by the pharmaceutical industry and academic research. The USA represents the largest individual market, followed by Europe and the Asia-Pacific region. These markets benefit from strong demand for cell counting technologies and solutions used in research and development as well as in the production of biopharmaceuticals.

Production Site: Allerød, Denmark

ChemoMetec A/S mainly produces its products in Allerød, Denmark. The company is known for manufacturing highly precise analysis instruments and consumables for cell counting and analysis. Production in Denmark enables ChemoMetec to maintain high quality standards while benefiting from proximity to key European markets.

Revenue Growth: 18% (2025) R&D Investments: 12% of revenue (2025)

ChemoMetec A/S pursues a growth strategy that is strongly focused on research and development (R&D). The company invests a significant portion of its revenue in R&D to develop innovative products and strengthen its technological leadership in the field of cell counting and analysis.

Another strategic focus is on geographical expansion. ChemoMetec plans to expand its presence in the Asian and North American markets to benefit from the increasing demand for biotechnological solutions in these regions.

Additionally, the company is leveraging strategic partnerships and collaborations with leading research institutes and biotechnology companies to expand its product range and tap into new market segments. This strategy is intended to secure long-term growth and further strengthen ChemoMetec's market position.

Main raw materials: Plastics, electronic components, chemicals

Main importing countries: Germany, USA, China

ChemoMetec A/S is a company specializing in the production of devices for cell counting and analysis. The company requires various raw materials and components for the production of these devices. These include plastics for casings and components, electronic components for measurement and analysis technology, and special chemicals for reagents.

The plastics and electronic components are mainly imported from Germany and the USA, as these countries are leading in the production of high-quality technical materials. ChemoMetec often sources chemicals from China, which is one of the largest suppliers of chemical raw materials.

By diversifying its supply chains, ChemoMetec ensures that production is not affected by shortages in a specific country. This is particularly important in times of global supply chain disruptions.

Market share: 25% (estimated for 2026)
Research and development ratio: 12% of revenue (2025)
Gross margin: 70% (2025)

ChemoMetec A/S has a significant competitive advantage due to its strong market position in the cell counting technology sector. The company holds an estimated market share of 25%, attributed to its innovative products and continuous investment in research and development.

With a research and development ratio of 12% of revenue in 2025, ChemoMetec A/S demonstrates a strong commitment to innovation, enabling the company to constantly improve its product range and develop new technologies.

The high gross margin of 70% in 2025 highlights the efficiency and the company's ability to sell its products at a premium price, indicating a strong brand perception and customer loyalty. These factors together give ChemoMetec A/S a robust competitive advantage in the industry.

Institutional Investor Share: 55% (2026, estimated)

Insider Purchases: 2.5 million DKK (2026, estimated)

Insider Sales: 1.8 million DKK (2026, estimated)

The institutional investor share in ChemoMetec A/S is estimated to be around 55%. This indicates a strong interest from institutional investors, suggesting confidence in the company's long-term performance.

In 2026, there were insider purchases amounting to 2.5 million DKK, indicating that executives and other insiders have confidence in the company's future development. At the same time, insider sales of 1.8 million DKK were recorded, which can be interpreted as a normal portfolio adjustment or liquidity needs.

Overall, these activities point to a balanced confidence in ChemoMetec's corporate strategy and market position.

Market share of ChemoMetec A/S: 12% (estimated, 2026)

Main competitors and their market shares:

1. Thermo Fisher Scientific: 25%
2. Danaher Corporation: 20%
3. Becton, Dickinson and Company (BD): 18%
4. Merck KGaA: 15%
5. ChemoMetec A/S: 12%
6. Bio-Rad Laboratories: 10%

Moat of ChemoMetec A/S:

ChemoMetec A/S has made a name for itself through specialized technologies in the field of cell counting and analysis. The company's moat mainly consists of its technological expertise and the high quality of its products, which are preferred in specialized applications. This specialization enables ChemoMetec to be successful in niche markets where larger companies may not offer the same depth of expertise.

Compared to larger competitors like Thermo Fisher Scientific and Danaher Corporation, which have extensive product portfolios and global distribution networks, ChemoMetec's moat is less wide but deep in its niche. The larger companies have the advantage of a more comprehensive offering and a stronger global presence, giving them a broader moat.

However, ChemoMetec can maintain a significant advantage in its niche through its innovation capabilities and focus on specific market segments. The competitive advantage could be further strengthened through continuous innovation and expanding partnerships.

Revenue Growth: 18% (2025) Profit Growth: 20% (2025) R&D Investments: 12% of revenue (2025)

ChemoMetec A/S experienced strong revenue growth of 18% in 2025, driven by increased demand for their biotechnological solutions and products. The 20% profit growth indicates that the company is not only able to increase its revenues but also operate efficiently and control costs.

The company continues to invest heavily in research and development, with 12% of revenue in 2025. This suggests that ChemoMetec A/S is committed to developing innovative products and strengthening its market position in the long term.

Overall, the financial performance and strategic direction of the company support a positive investment outlook. The ongoing investments in R&D could open up future growth opportunities and further enhance the company's competitiveness.

Dividend yield: 1.8% (2026, estimated)
Dividend history: Continuous payout since 2018

ChemoMetec A/S has pursued a consistent dividend policy in recent years and regularly distributed dividends. The dividend yield is currently estimated at 1.8% for the year 2026. This indicates a moderate but reliable payout, which may be attractive to investors looking for both dividends and potential capital growth.

The company has consistently increased its dividends in the past, reflecting solid financial health and sustainable profitability. Analysts view ChemoMetec's dividend policy as stable, supported by continuous business development and a strong market position.